AERI — Aerie Pharmaceuticals Share Price
Last Trade - 00:00- $689.14m
- $722.87m
- $94.92m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 24.18 | 69.89 | 83.14 | 111.81 | 165.49 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
Directors
- Vicente Anido CHM (68)
- Thomas Mitro (63)
- Casey Kopczynski (59)
- Richard Rubino CFO (63)
- John Larocca (56)
- David Hollander (47)
- Benjamin Mcgraw LED (72)
- Gerald Cagle (76)
- Richard Croarkin (66)
- Mechiel Du Toit (68)
- David Gryska IND (64)
- Peter Mcdonnell (63)
- Julie Mchugh (56)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- June 22nd, 2005
- Public Since
- October 25th, 2013
- No. of Shareholders
- 211
- No. of Employees
- 365
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 47,233,646
- Address
- 4301 Emperor Blvd Ste 400, DURHAM, 27703-7615
- Web
- http://www.aeriepharma.com/
- Phone
- +1 9192375300
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AERI
Upcoming events for AERI
Citi BioPharma Conference (Virtual)
Aerie Pharmaceuticals Inc at Citi Biopharma Conference
Q3 2021 Aerie Pharmaceuticals Inc Earnings Release
Similar to AERI
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ACELRX PHARMACEUTICALS ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
FAQ
As of Today at 19:56 UTC, shares in Aerie Pharmaceuticals are trading at $14.59. This share price information is delayed by 15 minutes.
Shares in Aerie Pharmaceuticals last closed at $14.59 and the price had moved by +14.34% over the past 365 days. In terms of relative price strength the Aerie Pharmaceuticals share price has underperformed the S&P500 Index by -13.25% over the past year.
The overall consensus recommendation for Aerie Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Aerie Pharmaceuticals does not currently pay a dividend.
Aerie Pharmaceuticals does not currently pay a dividend.
Aerie Pharmaceuticals does not currently pay a dividend.
To buy shares in Aerie Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $14.59, shares in Aerie Pharmaceuticals had a market capitalisation of $689.14m.
Here are the trading details for Aerie Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: AERI
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Aerie Pharmaceuticals does not currently have a style classification.
The analyst consensus target price for shares in Aerie Pharmaceuticals is $27.27. That is 86.91% above the last closing price of $14.59.
Analysts covering Aerie Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.51 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aerie Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -21.83%.
As of the last closing price of $14.59, shares in Aerie Pharmaceuticals were trading -8.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Aerie Pharmaceuticals.
Aerie Pharmaceuticals' management team is headed by:
- Vicente Anido - CHM
- Thomas Mitro -
- Casey Kopczynski -
- Richard Rubino - CFO
- John Larocca -
- David Hollander -
- Benjamin Mcgraw - LED
- Gerald Cagle -
- Richard Croarkin -
- Mechiel Du Toit -
- David Gryska - IND
- Peter Mcdonnell -
- Julie Mchugh -
We do not have data on Aerie Pharmaceuticals' shareholders